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 ABSTRACT  
Objective. Affective disorders are prevalent and burdensome conditions. Among medications 
prescribed at the onset, benzodiazepines (BZDs) are frequently administered, despite not being 
guideline-recommended. The present study sought to identify clinical variables associated with first 
BZD prescription, in order to elucidate reasons for their initial administration, in 460 patients with 
mood or anxiety disorders. 
Methods. Statistical analyses (one-wayANOVA and χ2test) were conducted to compare patients 
who received BZD as first treatment (BZDw/) and those who did not (BZDw/o). 
Results. In the whole sample more than 1/3 (35.7%) had received BZDs as first prescription. In 
relation to mood disorders, BZDw/ subjects more frequently had 1) not a psychiatrist as first 
therapist, 2) anxious symptoms at onset, 3) Adjustment Disorder (AD) as first diagnosis, 4) were 
less frequently treated as inpatients. In relation to specific diagnoses, 1) personal decision of 
treatment for Major Depressive Disorder, 2) outpatient status for Bipolar Disorder and 3) longer 
duration of untreated illness for AD were more frequently associated with first BZD prescription. 
For anxiety disorders, BZDw/ was related to the presence of stressful life events and to diagnoses of 
Panic Disorder or specific phobias. 
Conclusion. Patients with affective disorders were found to frequently receive BZDs as first 
prescription with significant differences between and within mood and anxiety disorders.   
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 INTRODUCTION 
Affective disorders are prevalent, comorbid and burdensome conditions with a frequent chronic 
course of illness (Charara et al., 2017). Especially for mild forms of illness, patients with affective 
disorders are not treated in psychiatric services, being frequently managed by general practitioners 
(GPs) (Baldwin, Allgulander, Bandelow, Ferre, & Pallanti, 2012; Dell’Osso et al., 2015; Dell’Osso 
& Lader, 2013). The tendency to be initially treated by GPs rather than psychiatrists might be 
related to the stigma towards mental illnesses and psychotropic drugs (Del Vecchio et al., 2015; 
Falloon, 2000; Skeate, Jackson, Birchwood, & Jones, 2002; Tait, Lester, Birchwood, Freemantle, & 
Wilson, 2005). Particularly at the onset of psychiatric symptoms, when a proper diagnosis is 
missing or when the symptomatology is underestimated (Dell’Osso et al., 2016), patients may be 
initially treated with symptomatic drugs, particularly with benzodiazepines (BZDs). In fact, these 
compounds are among the most widely prescribed classes of psychotropics, regardless of the 
diagnosis (Dell’Osso & Lader, 2013).(Busto & Sellers, 1991)(Bushnell, Stürmer, Gaynes, Pate, & 
Miller, 2017; Paquin, Zimmerman, & Rudolph, 2014) For this reason, many studies investigating 
BZDs prescription patterns at the onset of different psychiatric disorders (Straand & Rokstad, 
1997), emphasized, in particular, how these compounds are frequently misused and highlighted the 
importance to decrease their inappropriate use. Nonetheless, BZDs are often administered 
inappropriately to elderly population and patients often hesitate to discontinue BZDs, due to 
symptoms of withdrawal or relapse (Bushnell, Stürmer, Gaynes, Pate, & Miller, 2017; Paquin, 
Zimmerman, & Rudolph, 2014). BZDs have moreover well-established efficacy and safety, but also 
abuse potential abuse, and prolonged self-administration of low doses may be maintained to 
alleviate withdrawal symptoms (Busto & Sellers, 1991). 
BZDs are often prescribed in different psychiatric disorders (Dell’Osso & Lader, 2013; Nardi et al., 
2010)., including mood and anxiety disorders. Nonetheless, among available medications, BZDs are 
not recommended for mood disorders by International treatment guidelines, considering the lack of 
antidepressant effect and risk of long-term side effects (B Dell’osso & Lader, 2013). Similar 
limitations exist for anxiety disorders. In fact, high-potency BZDs are widely used in the treatment 
of panic disorder because of their rapid onset of action and favourable acute tolerability, ignoring 
relevant discontinuation symptoms that can occur after long-term use (Antonio E Nardi et al., 
2010). 
 
In light of the above, when recommended, BZDs should be administered in affective disorders 
exclusively as an adjunctive acute treatment, in order to avoid the long-term risk of abuse/addiction 
(Janhsen, Roser, & Hoffmann, 2015) and even short-term users should be aware of the potential risk 
of dependence(Anthierens et al., 2007).  Straand and Rokstad previously observed in a large 
population study (3452 patients) that 81.9% of BZD prescriptions were repeated ones, underlying 
the potential risk of dependence and the difficulty of BZD  discontinuation (Straand & Rokstad, 
1997).  theMoreover, a recent Norwegian study reported that a diagnosis of psychiatric disorder and 
the use of BZDs as first treatment choice could be risk factors for subsequent BZDs misuse (Fride 
Tvete, Bjørner, & Skomedal, 2015). Focusing on BZDs as first pharmacological prescription, our 
group previously reported that their initial administration could delay the implementation of a 
guideline-recommended adequate treatment (i.e., increasing the duration of untreated illness or 
DUI) in a large sample of patients affected by different psychiatric disorders (Grancini et al., 2018).  
Therefore, in the present study, we quantified first BZD prescription in total patients and related 
groups and then assessed clinical variables associated with BZDs first prescription in patients with 
affective disorders, with a specific focus on first therapist (psychiatrist/non psychiatrist). 
Secondarily, we tried to characterize patients with BZDs first prescription across specific affective 
disorders. We hypothesized to find different rates of BZD first prescription between patients with 
mood spectrum vs anxiety spectrum disorders along with distinct clinical variables associated to 
their use.  
 
METHODS  
For the present study, 460 in and out-patients, recruited in three major psychiatric services in the 
North and South of Italy, were analysed. Details related to catchment areas have been specified 
elsewhere (Grancini et al., 2018).  In order to obtain the psychiatric diagnosis and collect socio-
demographic and clinical variables, patients underwent a clinical interview after providing their 
written informed consent to participate to the study. Collected variables were additionally integrated 
through patients’ clinical records review. The Diagnostic and Statistical Manual of Mental 
Disorders, 4th ed., Text Revision (DSM IV-TR) (American Psychiatric Association, 2000) was 
used to assess patients’ diagnosis. Total sample was then divided in two diagnostic groups: 304 
patients with mood spectrum disorders (193 subjects affected by Major Depressive Disorder 
(MDD), 83 by Bipolar Disorder (BD) and 28 by Adjustment Disorder (AD)) and 156 patients with 
anxiety spectrum disorders (71 subjects with of Generalized Anxiety Disorder (GAD), 49 Panic 
Disorder (PD) and 36 Obsessive Compulsive Disorder (OCD)). e.g.Diagnoses were made through 
the Structured Clinical Interview for DSM-IV Axis I disorders (First MB, Michael B, 2002), 
administered by psychiatrists with specific training.  
 
Assessment  
Main demographic and clinical variables, collected during clinical interviews, were: gender, age, 
age at onset, age at first diagnosis, age at first pharmacological treatment, first pharmacological 
treatment, family history for psychiatric disorders, occurrence of onset-related stressful events, use 
of BZDs as first treatment, first therapist (psychiatrist, psychologist, GP or other clinician), help-
seeking decision (autonomous or driven by others) and first therapy setting (outpatient or inpatient). 
In particular, all patients were administered the psychopathological onset and latency to treatment 
questionnaire (POLT-Q), a recently developed tool aimed to specifically assess factors 
characterizing access and latency to first pharmacological treatment in patients suffering from 
psychiatric disorders. POLT-Q is a brief, clinician administered questionnaire that was found to be 
easy to administer by clinicians and well-accepted by patients (Dell’Osso B, Palazzo C, 2011). As 
conventionally accepted (Dell’osso & Altamura, 2010; Dell’Osso, Camuri, Benatti, Buoli, & 
Altamura, 2013), DUI was defined as the time interval – in months – elapsing between the onset of 
the disorder and the administration of the first pharmacological treatment, in compliant subjects, at 
appropriate dosage and for an adequate period of time, in agreement with recently updated 
International treatment guidelines of affective disorders (Bauer et al., 2013; Grunze et al., 2013). In 
case of comorbidity, the assessed disorder was considered the one causing the most significant 
discomfort to the patient, the greatest impact on his/her quality of life and representing the main 
motivation for help-seeking. 
 
Statistical analysis 
Descriptive and comparative analyses were performed within the two diagnostic groups and across 
specific diagnoses. Study sample was divided into two subgroups according to the use of BZDs as 
first treatment. One-way ANOVA for continuous variables and χ2 test for dichotomous ones were 
performed for comparison between patients who used BZDs as first treatment (BZD w/) and those 
who did not (BZD w/o), with Bonferroni’s correction. The level of significance for all statistical 
analyses was set at 0.05. 
 
RESULTS 
Demographic and clinical variables of the whole sample and related subgroups (n=460) are 
summarized in Table 1.  
A similar gender distribution emerged (male 51.3% and females 48.7%), with a mean age of 
48.57±14.35 years. The DUI of the total sample resulted to be 62.28±103.16 months.  
In the whole sample more than 1/3 of the subjects (35.7%) had received BZD as first prescription, 
with a slightly higher proportion of BZD w/ in the group of mood disorders compared to anxiety 
disorders (36.8% vs 33.3% p=0.46). 
In the subgroup of patients with mood spectrum disorders (n=304), 37% (n=112) of patients 
reported a first prescription with BZD, while in the sample with anxiety spectrum disorders (n=156) 
33% (n=52) had been initially treated with a BZD. Statistically significant differences between 
BZD w/ and BZD w/o for patients with mood and anxiety spectrum disorders and related diagnoses 
are reported in Table 2.  
In the context of mood disorders, BZD w/ patients were more frequently outpatients than inpatients 
(respectively 88.9% vs 77.5%, p<0.05 and 11.7% vs 22.5%, p<0.05) and more often had anxious 
symptoms at onset (22.3% vs 10.5%, p<0.01), while depressive, psychotic or other symptoms at 
onset did not show different rates between the two considered groups. Moreover, BZD w/ subjects 
were more frequently affected by AD (14.3% vs 6.3%, p<0.001) and less frequently by BD (16.1% 
vs 33.9%, p<0.001) compared to BZD w/o ones, while MDD prevalence did not result significantly 
different between the two groups, after Bonferroni’s correction. Psychologists or other doctors (in 
particular GPs) were more frequently the first professionals treating BZD w/ vs w/o patients 
(respectively 22.3% vs 7.9%, p<0.0001; 51.3% vs 38.2%, p<0.0001) compared with psychiatrists 
(25.9% vs 53.9%, p<0.0001). Other socio-demographic and clinical features did not show any other 
statistically significant difference between the two subgroups.  
Taking into consideration specific diagnoses of mood spectrum disorders, among patients with 
MDD, BZD w/ patients more frequently sought professional help following a personal decision 
compared to BZD w/o ones (53.5% vs 38.5%, p<0.05). Moreover, psychologists more frequently 
were the first therapists (21.8% vs 11.3%, p<0.01) compared to psychiatrist (23.1% vs 43.5%, 
p<0.01). Among bipolar subjects, BZD w/ ones were more frequently outpatients (88.9% vs 59.4%, 
p<0.05) than inpatients (11.1% vs 40.6%, p< 0.05). Finally, the DUI was found to be longer in BZD 
w/ patients affected by AD (38.3±63.2 vs 3.0±5.4 months, p<0.05). 
Considering the anxiety spectrum disorders, gender, presence of phobias and stressful life events 
significantly differed among BZDs w/ vs BZD w/o patients. More in detail, BZD w/ subjects were 
more frequently of female gender (60.0% vs 35.0%, p<0.01) and more often presented phobias 
(47.0% vs 23.0%, p<0.01) and stressful events (79.0% vs 58%, p<0.05) than BZD w/o ones. As in 
the mood spectrum disorders, the first therapist in BZD w/ patients was less often a psychiatrist 
(17.0% vs 48.0%, p<0.01) and more frequently other therapist (62.0% vs 40.0%, p<0.01). 
Furthermore, GAD diagnosis was more common in BZD w/ patients (58.0% vs 39.0%, p<0.05), 
while OCD diagnosis was less frequent (10.0% vs 30.0%, p<0.05). Analyses within specific 
diagnoses (OCD, GAD and PD) did not show any statistically significant difference. 
 
DISCUSSION 
In the present study, we aimed to quantify first BZD prescription and to assess related clinical 
variables in a large sample of patients with mood and anxiety disorders. In addition, we tried to 
characterize patterns of BZDs’ first prescription across specific diagnoses, due to the paucity of data 
in the field. 
Focusing on BZD w/ patients, representing more than one thirs of the overall sample and, 
respectively, the 37% of the mood disorders group and the 33% of the anxiety one, descriptive 
analyses showed a mean time elapsing from the first BZD use and the first prescription of an 
adequate (non symptomatic) pharmacological treatment of 48.01±79.15 months: approximately 4 
years. This finding indicates that patients, who initially had received a BZD prescription, ended up 
receiving a guideline-recommended different treatment years later. This gap likely reflects the mean 
latency to first diagnosis, which was found to exceed three years on average.  
In the context of mood disorders, BZD w/ patients were more frequently outpatients than inpatients 
(respectively 88.9% vs 77.5%, and 11.7% vs 22.5%), particularly among bipolar subjects 
(outpatients 88.9% vs 59.4%; inpatients 11.1% vs 40.6%). In fact, as symptomatic drugs (Verster & 
Volkerts, 2004), BZDs provide a fast relief for insomnia and comorbid anxious symptoms, 
especially for outpatients, who tend to start taking these medications at their home. Indeed, patients 
who were firstly administered BZDs presented more often anxious symptoms at onset (22.3% vs 
10.5%), while depressive, psychotic or other onset symptoms did not differ between groups. Nardi 
and colleagues previously confirmed the aforementioned association between anxious symptoms 
and use of BZDs in patients with mood spectrum disorders (Nardi et al., 2008). Nonetheless, the 
presence of anxious symptoms should rather be considered a reason to start a guideline-
recommended treatment, like a second-generation antidepressant, rather than a BZD(Baldwin et al., 
2014). (Gaspersz, Nawijn, Lamers, & Penninx, 2018) 
BZD w/ subjects were more frequently affected by AD (14.3% vs 6.3%) and less frequently by BD 
(16.1% vs 33.9) compared to BZD w/o ones, while no difference emerged in relation to MDD rates. 
A previous study with a large sample showed that more than 50% of the AD patients were disabled 
by their symptoms, with frequent BZDs administration (Arbus et al., 2014). Actually, a limited 
literature on BZDs use in patients with AD is available and, to date, no specific psychotropic has 
been approved for this indication (Casey, 2014). Of note, the DUI was found to be longer in BZD 
w/ vs BZD w/o patients affected by AD (38.3±63.2 vs 3.0±5.4 months). 
Another relevant finding of the present study indicates that psychologist or other therapists (in 
particular GPs) more frequently represented the first therapist for BZD w/ patients (respectively 
22.3% vs 7.9%; 51.3% vs 38.2%), rather than psychiatrists (25.9% vs 53.9%). The same result was 
found for MDD (psychologist 21.8% vs 11.3%, psychiatrist 23.1% vs 43.5%) and for anxiety 
spectrum disorders (psychiatrist 17.0% vs 48.0%, other doctor 62.0% vs 40.0%; Figure 1). Previous 
investigation reported converging results both in Italian (Dell’Osso et al., 2015) and European 
samples. In this perspective, Alonso and colleagues in the ESEMeD study showed that only 25.7% 
of individuals with a previous 12-month diagnosis of mental disorder used a formal health service 
(i.e., psychiatrist, psychologist, specialized nurse, general practitioner, or any other medical doctor). 
Among these, 33.4% consulted a GP, 19.6% a psychiatrist, 13.5% a psychologist/counsellor and 
28% both a GP and a mental health professional. Formal mental health service use was more 
frequent among individuals with mood compared to anxiety disorders. Among European countries, 
Italy showed a lower, statistically significant likelihood of consultation with formal health services 
(Alonso et al., 2004). Taken as a whole, these results seem to support the view that BZDs may be 
more frequently prescribed by non-psychiatrist therapists in patients with mood spectrum disorders. 
In addition, this finding seems to be linked to the observed delayed latency to first diagnosis, 
previously discussed, which converge in defining an incorrect and dangerous approach to mental 
health services for many patients with affective disorders, based on the following assumptions: 
minor presence of psychiatrist as first therapist, more frequent first BZD prescription, long latency 
to first diagnosis and, ultimately, longer DUI (i.e., longer latency to a guideline-recommended 
treatment (e.g., antidepressants, mood stabilizers). 
Focusing on pharmacological prescriptions, indeed, BZDs are frequently prescribed in mood 
disorders as initial treatments (Baldwin et al., 2012; Dell’Osso & Lader, 2013), even though 
treatment guidelines recommend the use of an antidepressant treatment (Baldwin et al., 2014; 
Starcevic, 2014). Actually, Bushnell and colleagues showed, in a large sample of 765 depressed 
patients, no significant clinical differences in continuation of antidepressant treatment between 
simultaneous administration of BZDs plus antidepressant and antidepressant alone (Bushnell et al., 
2017; Rizvi, Sproule, Gallaugher, McIntyre, & Kennedy, 2015a).  (Benasi et al., 2018)Furthermore, 
as BZD dependence may develop shortly after their initial administration (Lader, 1991; Youssef & 
Rich, 2008), BZDs in mood disorders should be more cautiously prescribed. 
Interestingly, in relation to the specific diagnosis of MDD, BZD w/ patients more frequently sought 
for treatment following a personal decision than BZD w/o ones (53.5% vs 38.5%, p<0.05). 
Demyttenaere and colleagues, in the ESEMeD project study, reported that help seeking behaviour 
(defined as consultation with any of formal healthcare providers, such as psychiatrist, psychologist, 
general practitioner or any other medical doctor) significantly increased the use of BZDs compared 
to non-help seeking subjects (Demyttenaere et al., 2008). Our findings and Demyttenaere’s report 
might therefore suggest that the use of BZDs as first therapy is common among patients suffering 
from mood and anxiety disorders, and particularly among those who then decide to autonomously 
seek for help.  
Considering anxiety spectrum disorders, BZD w/ subjects were more frequently females (60.0% vs 
35.0%) and more often presented phobias (47.0% vs 23.0%) and onset-related stressful life events 
(79.0% vs 58%) than BZD w/o ones. In this respect, female patients were found to be more 
frequently BZD users in several reports. Among those, Peters and colleagues analysed multiple 
demographic and clinical factors associated with BZD prescription at patients’ discharge from 
psychiatric unit, reporting that women had a greater likelihood of receiving BZDs (Peters, Knauf, 
Derbidge, Kimmel, & Vannoy, 2015). Also Demyttenaere and colleagues, in the ESEMeD study, 
reported that, beyond specific clinical factors, female gender was more frequently associated with 
BZD use in the last year (Demyttenaere et al., 2008). Moreover, other studies showed that BZD use 
tends to be higher in female patients not only when focusing on GPs prescriptions in the general 
population (Moßhammer et al., 2017), but also in patients suffering from depression, anxiety and/or 
insomnia (Rizvi, Sproule, Gallaugher, McIntyre, & Kennedy, 2015b; Sjöstedt, Ohlsson, Li, & 
Sundquist, 2017). 
Finally, in anxiety spectrum disorders, BZD w/ subjects were more frequently affected by GAD 
(58.0% vs 39.0%) and less frequently by OCD (10.0% vs 30.0%) than BZD w/o ones. This result 
can reflect current evidence regarding BZDs use in such conditions, wider for patients with GAD, 
even with a low overall guideline recommendation level. In fact, in the available literature, the role 
of BZDs in GAD is debated:(Dell’Osso & Lader, 2013)(Offidani, Guidi, Tomba, & Fava, 
2013)(Rickels & Moeller, 2018), these compounds having a rapid relief for anxiety symptoms 
despite their long-term side effects and abuse risk (B Dell’osso & Lader, 2013). (Balon et al., 2018) 
al(Fava & Belaise, 2018; Jha, Rush, & Trivedi, 2018) For instance, WFSBP guidelines ranked 
BZDs use in GAD with the highest category of evidence (A) and a moderate risk-benefit ratio, 
while their use is not mentioned in OCD (Bandelow et al., 2008), being poorly supported by 
available evidence.  
 
Even though our sample resulted to be quite representative, the following methodological 
limitations should be considered to interpret the aforementioned findings. Since the POLT-Q 
retrospectively collected socio-demographic and clinical variables, the presence of recall bias 
cannot be excluded, particularly for patients with most remote onset, like elderly people. 
Nonetheless, as already mentioned, all clinical data from the POLT-Q were cross-checked with 
family members/caregivers and previous medical charts, when available. Moreover, the recruitment 
of patients coming from different catchment areas may have reflected local differences in terms of 
efficiency of psychiatric services as well as different socio-cultural attitudes, which, in turn, may 
have influenced reported results. Indeed, the prevalence of BZDs prescription varied considerably 
across different populations and several clinical factors could have influenced the results, including 
the epoch of recruitment, with patients with more recent onset having likely access to more suitable 
pathways of mental health care compared with individuals with a more distant onset, as we 
previously pointed out (Dell’Osso et al., 2016) 
 
CONCLUSION 
We contend that the identification of socio-demographic and clinical aspects related to potentially 
inappropriate initial prescription of BZDs in affective disorders could be highly useful to prevent 
subsequent misuse and related side effects and risks (Baldwin et al., 2013). Consequently, a more 
careful psychiatrist-oriented approach to first diagnosis and pharmacological prescription might 
reduce the incorrect prescription of first BZDs and a delayed latency to first diagnosis and first 
guideline-recommended treatment in patients with affective disorders, likely limiting BZD related 
long-term side effects, abuse and withdrawal concerns (Donoghue & Lader, 2010), with the 
ultimate aim to early begin an adequate treatment rather than a symptomatic therapy. Further 
replication studies are needed to corroborate our results. 
 
Table 1. Socio-demographic and clinical variables of the total sample and related subgroups (BZDs w/ and 
BZD w/o). 
 Total Sample BZDw/o  (n=296) BZDw/ (n=164) 
Gender: male 







Age (years) 48.57±14.35 48.51±13.83 48.68±15.23 
Age at onset (years) 32.26±14.27 32.10±14.27 32.54±14.30 
Age of first diagnosis (years) 36.81±13.99 36.58±13.87 37.23±14.24 
Age at first pharmacological treatment (years) 37.45±14.11 36.66±13.42 38.87±15.23 
DUI (years) 5.19±8.60 4.56±8.25 6.33±9.11 
DUI (months) 62.28± 103.16 54.70± 98.96 75.96± 109.33 
Time between BZD treatment-OTHER treatment 
(months) 
48.01±79.15 - 48.01±79.15 
Age at first BZD treatment 35.43±14.25 - 35.43±14.25 
 
 
 Table 2. Socio-demographic and clinical features of BZDw/ vs and w/o in patients with mood and 
anxiety spectrum disorders and related diagnoses. 
MOOD SPECTRUM DISORDERS 
VARIABLES BZD w/o (192) BZD w/ (112) Total sample (304) p 
Onset symptoms  
 
Anxious 20 (10.5%) 25 (22.3%) 45 (14.9%) ** 
Depressive 84 (44.0%) 41 (36.6%) 125 (41.3%) 
Psychotic 17 (8.9%) 4(3.6%) 21(6.9%) 
Anxious/depressive 16 (8.4%) 2 (1.8%) 18 (5.9%) 
Others  54 (28.3%) 40 (35.7%) 94 (31.0%) 
Diagnosis MDD 115 (59.9%) 78 (69.6%) 193 (63.5%) *** 
BD 65 (33.9%) 18 (16.1%) 83 (27.3%) 
Adjustment 12 (6.3%) 16 (14.3%) 28 (9.2%) 
1st Therapist Psychiatrist 103 (53.9%) 29 (25.9%) 132 (43.6%) **** 
Psychologist 15 (7.9%) 25 (22.3%) 40 (13.2%) 
GP/Other Doctor 73 (38.2%) 58 (51.8%) 131 (43.2%) 
Outpatient vs inpatients Outpatient 148 (77.5%) 98 (88.3%) 246 (81.5%) * 
Inpatient 43 (22.5%) 13 (11.7%) 56 (18.5%) 
MAJOR DEPRESSIVE DISORDER 
VARIABLES BZD w/o (115) BZD w/ (78) Total sample (193) p 
Personal decision  Yes 42 (38.5%) 38 (53.5%) 80 (44.4%) * 
No 67 (61.5%) 33 (46.5%) 100 (55.6%) 
1st Therapist Psychiatrist 50 (43.5% ) 18 (23.1%) 68 (35.2%) ** 
Psychologist 13 (11.3% ) 17 (21.8%) 30 (15.5%) 
GP/Other Doctor 52 (45.2%) 43(55.1%) 95 (49.2%) 
BIPOLAR DISORDERS 
VARIABLES BZD w/o (65) BZD w/ (18) Total sample (83) p 
Outpatient vs inpatients Outpatient 38 (59,4%)  16( 88,9%) 54 (65,9%) * 
Inpatient 26 (40,6%) 2 (11,1%) 28 (34,1%) 
ADJUSTMENT DISORDER 
VARIABLES BZD w/o (12) BZD w/ (16) Total sample (28) p 
DUI (years) 0.3±0.5 3.2±5.3 1.9±4.2 * 
DUI (month) 3.0±5.4 38.3±63.2 23.1±50.5 * 
ANXIETY SPECTRUM DISORDERS 
VARIABLES BZD w/o (104) BZD w/  (52) Total sample (156) p 
Gender 
 
Male 62 (60%) 18 (35%) 80 (51%) ** 
Female 42 (40%) 34 (65%) 76 (49%) 
Diagnosis OCD 31 (30%) 5 (10%) 36 (23%) * 
GAD 41 (39%) 30 (58%) 71 (46%) 
PD 32 (31%) 17 (33%) 49 (31%) 
1st Therapist Psychiatrist 50 (48%) 9 (17%) 59 (38%) ** 
Psychologist 12 (12%) 11 (21%) 23 (15%) 
GP/ Other Doctor 42 (40%) 52 (62%) 74(47%) 
Phobia Yes 22 (23%) 24 (47%) 46 (31%) ** 
No 74 (77%) 27 (53%) 101(69%) 
Stressful events Yes 60 (58%) 41 (79%) 101 (65%) * 





Legend: BZD: benzodiazepine (BZD w/: patients with BZD as first treatment; BZD w/o: patients without). T: treatment. MDD: Major Depressive 
Disorder. BD: Bipolar Disorder. OCD: Obsessive Compulsive Disorder. GAD: Generalized Anxiety Disorder. PD: Panic Disorder. DUI: Duration of 
Untreated Illness. 
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